It was a placement at 3.5 when bpo has been weak which is a good sign.They probably know more about re gen and bioeffective progress than we do. They were given bpoob plus 2013 5c options. We'll find out soon in the quarterly. They won't be able to get any value out of bpoob if it stays where it is till march. A one cent rise in a day is possible let alone 2 months. The active ingredient eremophilone oil will have it's statutory period of evaluation completed by the end of feb with APVMA which could also have a bearing on the price of bpo. Just keep an eye on the buy depth building and the sell depth slowly withdrawn. Don't sell your bpoob yet cav.
BPO Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
